Page 153 of 449: studies 1,521 to 1,530 of 4,486, newest first. Back to the ketamine overview
JAMA Psychiatry December 1, 2023 Chittaranjan Andrade
This Viewpoint discusses ketamine and its new and experimentally investigated on- and off-label indications that span different medical disciplines.
JAMA Psychiatry December 1, 2023 Sanjay J. Mathew, Manish K. Jha, Amit Anand 8 citations
This Viewpoint examines key issues stemming from several recent reports of electroconvulsive therapy (ECT) vs ketamine for improving depressive symptoms in treatment-resistant depression (TRD).
Pharmacology, Biochemistry, and Behavior December 1, 2023 Guilin Liu, Li Ma, Youge Qu et al. 16 citations
Anesthetic ketamine and classical psychedelics that act as 5-hydroxytryptamine-2A receptor (5-HT2AR) agonists demonstrated rapid and sustained antidepressant actions in patients with treatment-resistant depression. The new antidepressant arketamine is reported to cause long-lasting prophylactic effects in lipopolysaccharide (LPS)-treated mice and mice exposed to chronic restrain stress (CRS)....
Drug and Alcohol Dependence December 1, 2023 Caryssa R Drinkuth, Michael J Lehane, Gregory C Sartor 9 citations
Despite the thousands of lives lost during the ongoing opioid crisis, a scarcity of new and effective clinical treatments for opioid use disorder (OUD) remains. To address this unmet need, some researchers have turned to dissociative and psychedelic drugs to treat multiple psychiatric conditions. In particular, low doses of ketamine have been shown to attenuate opioid withdrawal and drug use in...
medRxiv Preprint Server December 1, 2023 Brandon Taraku, Joana R Loureiro, Ashish K Sahib et al. 1 citation preprint
Dysfunctional reward processing in major depressive disorder (MDD) involves functional circuitry of the habenula (Hb) and nucleus accumbens (NAc). Ketamine elicits rapid antidepressant and alleviates anhedonia in MDD. To clarify how ketamine perturbs reward circuitry in MDD, we examined how serial ketamine infusions (SKI) modulate static and dynamic functional connectivity (FC) in Hb and NAc...
Proceedings of the National Academy of Sciences November 27, 2023 John H. Krystal, Alfred P. Kaye, Sarah J. Jefferson et al. 66 citations
Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and protection against relapse distinguish it from prior antidepressants. Its discovery emerged from a reconceptualization of the neurobiology of depression and, in turn, insights from the elaboration of its mechanisms of action...
European Psychiatry November 17, 2023 N. Veluri, Zeeshan Mansuri 1 citation
Introduction Globally, depression affects millions of individuals. A third of depression patients meet the criteria for treatment-resistant depression (TRD). The N-methyl-D-aspartate receptor antagonist, ketamine, improved depressive symptoms in a span of 24-hours. Recently, the FDA approved esketamine, an enantiomer of ketamine for TRD. Objectives To determine the effectiveness of ketamine and...
Australasian Psychiatry November 14, 2023 Judith D. Hope, David L Copolov, John Tiller et al.
Objective To review the usefulness of esketamine for treatment-resistant depression. Method Pivotal trials of intranasal esketamine in treatment-resistant depression were synthesized as a narrative review. Results Esketamine is postulated to act through antagonism of N-methyl-D-aspartate (NMDA) glutamate receptors, but opioidergic effects may also be involved. Unlike intravenous ketamine,...
Mental Health Weekly November 13, 2023 Valerie A. Canady
Observing that ketamine infusion therapy is increasingly being used for such mental health conditions as major depressive disorder, bipolar disorder, treatment‐resistant depression, and post‐traumatic stress disorder, two national nursing associations have released a joint statement indicating that patients with psychiatric disorders may benefit from the use of ketamine infusion therapy.
Pharmacology, Biochemistry, and Behavior November 8, 2023 Aida A.C. Brandão, D. L. S. Deus, L. A. Duarte-Filho et al.
Major depressive disorder (MDD) is a debilitating illness that affects millions of people worldwide. Currently available antidepressants often take weeks to months to reach their full effect, which leads to an increased risk of suicidal behavior in patients with MMD. Intranasally, esketamine has emerged as an alternative to current antidepressants because of its rapid onset and long-lasting...